The Fort Worth Press - MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

USD -
AED 3.672495
AFN 64.000314
ALL 82.253977
AMD 360.509431
ANG 1.790403
AOA 917.499428
ARS 1552.284702
AUD 1.48346
AWG 1.8025
AZN 1.697632
BAM 1.779545
BBD 2.01413
BDT 124.905034
BGN 1.77347
BHD 0.377331
BIF 3007.507166
BMD 1
BND 1.288858
BOB 11.66537
BRL 5.778804
BSD 1.000059
BTN 93.425596
BWP 13.998644
BYN 3.001178
BYR 19600
BZD 2.011401
CAD 1.42811
CDF 2317.999791
CHF 0.838815
CLF 0.025259
CLP 994.110012
CNY 6.66455
CNH 6.665535
COP 3315.05
CRC 445.481718
CUC 1
CUP 24.000873
CVE 100.328012
CZK 22.107101
DJF 177.720338
DKK 6.781775
DOP 60.559465
DZD 136.951012
EGP 53.7264
ERN 15
ETB 164.140883
EUR 0.90739
FJD 2.296803
FKP 0.758367
GBP 0.756145
GEL 2.594965
GGP 0.758367
GHS 11.73543
GIP 0.758367
GMD 73.501804
GNF 8860.460038
GTQ 7.643069
GYD 209.144677
HKD 7.846205
HNL 26.886001
HRK 6.831965
HTG 131.024035
HUF 332.705959
IDR 18268.2
ILS 3.254645
IMP 0.758367
INR 93.45945
IQD 1516.079284
IRR 1925253.999815
ISK 124.130485
JEP 0.758367
JMD 158.919789
JOD 0.709003
JPY 159.245985
KES 129.999866
KGS 87.448984
KHR 4080.072793
KMF 447.497229
KPW 900.00035
KRW 1334.25967
KWD 0.31158
KYD 0.833458
KZT 444.016797
LAK 22523.690592
LBP 89554.848894
LKR 332.782835
LRD 168.006442
LSL 16.919297
LTL 2.95274
LVL 0.60489
LYD 6.462884
MAD 9.981438
MDL 18.311519
MGA 4549.44565
MKD 55.861384
MMK 2099.8229
MNT 3605.49036
MOP 8.082545
MRU 40.524838
MUR 47.860197
MVR 15.410202
MWK 1734.212921
MXN 18.413075
MYR 4.093596
MZN 63.910227
NAD 16.918528
NGN 1348.670466
NIO 36.80602
NOK 9.59563
NPR 149.481136
NZD 1.81649
OMR 0.384501
PAB 1.000032
PEN 3.415635
PGK 4.499381
PHP 63.585016
PKR 276.505202
PLN 3.993785
PYG 6230.864068
QAR 3.64562
RON 4.852297
RSD 106.739941
RUB 82.05711
RWF 1480.116648
SAR 3.756442
SBD 8.098361
SCR 13.825232
SDG 601.499925
SEK 10.096805
SGD 1.287735
SHP 0.758581
SLE 23.049694
SLL 20969.503664
SOS 571.501363
SRD 37.437951
STD 20697.981008
STN 22.292284
SVC 8.750364
SYP 13002.000337
SZL 16.918877
THB 33.77702
TJS 9.216015
TMT 3.51
TND 3.026264
TOP 2.40776
TRY 50.414697
TTD 6.771395
TWD 32.925901
TZS 2650.002957
UAH 45.33545
UGX 4149.985442
UYU 40.627659
UZS 12019.053598
VES 914.603599
VND 25712.5
VUV 120.845902
WST 2.802705
XAF 595.208663
XAG 0.021073
XAU 0.000259007303
XCD 2.70255
XCG 1.802383
XDR 0.707052
XOF 595.208663
XPF 108.509428
YER 236.503646
ZAR 16.92348
ZMK 9001.222553
ZMW 20.486504
ZWL 321.999592
SSP 5946.953244
MXV 2.06566
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain

Text size:

Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company, proudly announces the successful completion of its current Good Laboratory Practice (GLP) preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results confirm no adverse findings, clearing a critical milestone as the Company progresses toward submitting its Investigational New Drug (IND) application by year-end 2024.

"Our commitment to advancing Ketamir-2 into clinical trials as quickly as possible reflects our strategic focus on generating proof-of-concept data that positions MIRA for a potential M&A transaction or strategic partnership," said Erez Aminov, CEO and Chairman of MIRA. "This milestone demonstrates our ability to execute efficiently and reinforces our dedication to delivering innovative, safe, and effective treatments for patients suffering from neuropathic pain."

The Significance of Safety in Drug Development

Safety is one of the most significant factors influencing the success of drug development and regulatory approval. Industry data shows that nearly 40% of drug failures during clinical development are attributed to safety concerns, making it a primary reason for termination at all stages of research. Additionally, drugs with unresolved safety questions often face post-market challenges, with 30% of FDA-approved drugs receiving post-market safety warnings or label changes.

By demonstrating Ketamir-2's robust safety profile in comprehensive preclinical studies, MIRA has significantly de-risked this critical aspect of drug development. This milestone positions the company for a smoother regulatory pathway and potentially increases the likelihood of successful clinical outcomes.

Highlights of Preclinical Findings:

  • Cardiovascular Safety in Dogs: No adverse effects were noted at therapeutic doses.

  • CNS Assessment in Rats: No significant CNS changes were observed at therapeutic dose levels, confirming a favorable safety profile. Effects in high-dose groups were limited, transient, and non-disruptive.

  • Respiratory Safety in Rats: No respiratory-related effects were noted across all tested doses.

  • 14-Day Toxicology in Dogs: Ketamir-2 was well-tolerated at daily doses up to 200 mg/kg, with no observed adverse effects. This dose established the No Observed Adverse Effect Level (NOAEL).

  • Ames Test: Ketamir-2 was confirmed to be non-mutagenic, further supporting its safety profile.

Path to Clinical Trials

With the current preclinical safety program successfully completed, MIRA remains on schedule to submit its IND application by the end of 2024. The Phase I clinical trial, set to begin in Q1 2025, is designed to gather critical insights into the safety, tolerability, pharmacokinetics, and pharmacodynamics of Ketamir-2 in healthy subjects. Importantly, the trial will include a robust battery of pain tests to evaluate the drug's effects on neuropathic pain and psychosis. These evaluations are expected to provide valuable data by Q2 2025, helping to better understand how Ketamir-2 affects pain in humans prior to initiating Phase IIa trials in patients.

This innovative study design allows for early efficacy data to be gathered in healthy volunteers, providing deeper insights into Ketamir-2's therapeutic potential and optimizing the design of future trials. Building on the Phase I findings, MIRA plans to initiate a Phase IIa proof-of-concept study in Q4 2025, focusing on patients with neuropathic pain. Proof-of-concept results are anticipated by year-end 2025, marking a transformative year as MIRA transitions into a clinical-stage pharmaceutical company.

Powerful Endorsement from Scientific Leadership

"The robust safety data we've generated for Ketamir-2 is nothing short of extraordinary," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "This is a pivotal moment, not just for MIRA, but for the millions of patients suffering from neuropathic pain who are waiting for a safe, non-addictive, and effective treatment. Ketamir-2 represents a groundbreaking step forward in addressing unmet medical needs, and I am confident that it has the potential to redefine treatment paradigms in this space. By strategically designing our Phase I trial to include a comprehensive pain evaluation, we are maximizing the insights we can gain early, positioning us to move into patient trials with a strong understanding of the drug's effects in humans."

A Safer Path to Addressing Unmet Needs

The need for safe, non-addictive treatments for neuropathic pain is pressing, with millions of patients worldwide seeking alternatives to existing therapies that often cause intolerable side effects. By addressing this unmet need with a drug that has a strong safety profile, MIRA aims to set a new standard in neuropathic pain management. Safety validation at this stage also reduces the risk of clinical delays, maximizes resource efficiency, and enhances the opportunity for meaningful collaborations.

Financial and Strategic Position

MIRA believes it has a strong financial position that can potentially ensure the resources necessary to achieve clinical milestones. The Company is actively exploring non-dilutive funding opportunities to accelerate development and maximize the therapeutic impact of Ketamir-2.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.

Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 432-9792

SOURCE: Mira Pharmaceuticals, Inc.

B.Martinez--TFWP